Sch772984

U0126 (Cat. # 1144, MEK inhibitor) and Go6976 (Cat. # 2253/1, PKCα inhibitor) were purchased from TOCRIS (Bristol UK). TBCA (Cat. # 934358–00–6, CK2 inhibitor) and S2101 (Cat. # 48977, LSD1 inhibitor) were purchased from Calbiochem (San Diego, CA, USA). SCH772984 (Cat. # CT-SCH772, ERK inhibitor) and Tamoxifen were purchased from Chemie Tek (Indianapolis, IN, USA) and Sigma, respectively. Dual-Luciferase Reporter Assay system was purchased from Promega (Madison, WI, USA).

Phospho-specific antibodies against ERK (Thr-202 and Tyr-204), Akt (Ser-473), p90RSK (Ser-380), EGFR (Thr-669), ErbB2 (Tyr-1196 and Tyr-1248) and ErbB3 (Tyr-1289), and total EGFR antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against EGFR, ErbB2, ErbB3, Akt1 and Actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Recombinant human epidermal growth factor (EGF), heregulin (HRG), and fibroblast growth factor-2 (FGF-2) were purchased from R&D Systems (Minneapolis, MN, USA). SB203580, SP600125, U0126, and LY294002 were obtained from Merck Biosciences (Darmstadt, Germany). Lapatinib and trametinib were obtained from AdooQ BioScience (Irvine, CA, USA) and Cayman Chemical (Ann Arbor, MI, USA), respectively. SCH772984 was purchased from Chemietek (Indianapolis, IN, USA). TPA and Phos-tag ligand were purchased from WAKO Pure Chemical Industries (Osaka, Japan). All chemical agents were dissolved in DMSO, and the final concentration of DMSO was less than 0.1%.